Dr. Reem Karmali
Claim this profileNorthwestern University
Expert in Cancer
Expert in B-Cell Lymphoma
16 reported clinical trials
31 drugs studied
Area of expertise
1Cancer
Global LeaderCCND1 positive
t(11;14) positive
MYC positive
2B-Cell Lymphoma
Global LeaderMYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Reem Karmali is currently running
Cell Therapy
for Non-Hodgkin's Lymphoma
This trial tests a new treatment where a patient's own immune cells are enhanced to fight difficult-to-treat lymphoma. It targets patients whose cancer hasn't responded to at least two other treatments. The modified cells aim to better recognize and attack the cancer. This new method improves the ability of the patient's immune cells to find and destroy cancer cells.
Recruiting1 award Phase 219 criteria
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
More about Reem Karmali
Clinical Trial Related1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Reem Karmali has experience with
- Rituximab
- Cyclophosphamide
- Nivolumab
- Pembrolizumab
- Lenalidomide
- Prednisone
Breakdown of trials Reem Karmali has run
Cancer
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Reem Karmali specialize in?
Reem Karmali focuses on Cancer and B-Cell Lymphoma. In particular, much of their work with Cancer has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Reem Karmali currently recruiting for clinical trials?
Yes, Reem Karmali is currently recruiting for 6 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Reem Karmali has studied deeply?
Yes, Reem Karmali has studied treatments such as Rituximab, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Reem Karmali?
Apply for one of the trials that Reem Karmali is conducting.
What is the office address of Reem Karmali?
The office of Reem Karmali is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.